Analyst Price Target is $70.00
▲ +683.00% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Annovis Bio in the last 3 months. The average price target is $70.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 683.00% upside from the last price of $8.94.
Current Consensus is
The current consensus among 2 polled investment analysts is to buy stock in Annovis Bio.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.